Examining FOLFIRINOX Resistance in Pancreatic Cancer through the Creation of Resistant Cell Culture Models
DOI:
https://doi.org/10.47611/jsr.v13i3.2661Keywords:
Pancreatic Cancer, Chemotherapy Resistance, RNA Sequencing, GI50Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive form of cancer with a 5-year survival rate of 8.5%. PDAC is often characterized by its early-stage metastasis, resistance to cytotoxic chemotherapy, and extremely poor prognosis. A leading treatment for patients who can tolerate its severe side effects is a cocktail of 4 chemotherapeutic drugs, leucovorin, 5-fluorouricil, irinotecan, and oxaliplatin (FOLFIRINOX). Despite FOLFIRINOX being a leading treatment for patients with pancreatic cancer, the cellular response to the treatment is poorly understood. This investigation focused on chemotherapy resistance to FOLFIRINOX in four PDAC cell lines. To determine initial sensitivity to the drug cocktail, PDAC cells were dosed with FOLFIRINOX at a ratio similar to that used clinically. Cell viability was assessed to calculate GI50 concentrations. The PANC 03.27 cell line was found to be the most sensitive to FOLFIRINOX with a GI50 concentration of 0.71 mM, while PANC 04.03 was found to have a GI50 value of 1.33 mM. These two cell lines were then cultured in FOLFIRINOX to create a clinically relevant model of chemotherapy resistance. To assess resistance, post-treatment GI50 assays were performed and demonstrated a 1.6-fold increase in FOLFIRINOX resistance in PANC 03.27 cells. Additionally, RNA Sequencing was performed on untreated control, DMSO control, and FOLFIRINOX-treated cells to identify changes in the transcriptome and possible mechanisms promoting chemotherapy resistance. Changes in gene expression accompanying resistance may lend insight into the underlying mechanism of resistance in FOLFIRINOX experienced by many patients with pancreatic cancer.
Downloads
Metrics
References or Bibliography
A. C. Society, "Pancreas Statistics," American Cancer Society- Cancer Facts & Statistics, [Online]. Available: https://cancerstatisticscenter.cancer.org/?_ga=2.14369534.812530307.1550618839-2022778819.1546709623#!/cancer-site/Pancreas. [Accessed 19 Febuary 2019].
R. L. Siegel, K. D. Miller and A. Jemal, "Cancer Statistics, 2016 Rebecca," CA: A Cancer Journal for Clinicians, vol. 67, no. 1, pp. 7-30, 2017.
J. P. Neoptolemos, R. Urrutia, J. L. Abbruzzese and M. W. Büchler, Pancreatic Cancer, New York: Springer, 2018.
National Cancer Institute, "Cancer Stat Facts: Pancreatic Cancer," National Instituteof Health , [Online]. Available: https://seer.cancer.gov/statfacts/html/pancreas.html. [Accessed 19 February 2019].
M. Gnanamony and C. S. Gondi, "Chemoresistance in pancreatic cancer: Emerging concepts (Review)," Oncology Letters, vol. 13, no. 4, pp. 2507-2513, 2017.
K. S, N. Karbasian, P. Bhosale, S. de Castro Faria, O. Le, M. H. Katz, E. J. Koay and E. P. Tamm, "Imaging findings of recurrent pancreatic cancer following resection," Abdominal Radiology, vol. 43, no. 2, pp. 489-496, 2017.
S. C. Chang, C. P. Hsu, C. Y. Tsai, Y. Y. Liu, K. H. Liu, J. T. Hsu, T. S. Yeh, C. N. Yeh and T. L. Hwang, "Selective reoperation after primary resection as a feasible and safe treatment strategy for recurrent pancreatic cancer," Medicine, vol. 95, no. 30, pp. 1-5, 2016.
A. Van den broeck, G. Sergeant, N. Ectors, W. Van Steenbergen, R. Aerts and B. Topal, "Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma," European Journal of Surgical Oncology, vol. 35, no. 6, pp. 600-604, 2009.
S. Mohammed, G. Van Buren and W. E. Fisher, "Pancreatic cancer: Advances in treatment," World Journal of Gastroenterology, vol. 20, no. 28, pp. 9354-9360, 2014.
T. Conroy, F. Desseigne, M. Ychou, O. Bouché, R. Guimbaud, Y. Bécouarn, A. Adenis, J. L. Raoul, S. Gourgou-Bourgade, C. De La Fouchardière, J. Bennouna and J. B. Bachet, "FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer," New England Journal of Medicine, vol. 364, no. 19, pp. 1817-1825, 2011.
A. Tsujimoto, K. Sudo, K. Nakamura, E. Kita, R. Hara, W. Takayama, H. Ishii and T. Yamaguchi, "Gemcitabine plus nab-paclitaxel for locally advanced or boarderline resectable pancreatic cancer," Scientific Reports, vol. 9, no. 16187, pp. 1-8, 2019.
A. Adamska, O. Elaskalani, A. Emmanouilidi, M. Kim, N. B. Abdol Razak, N. B. Abdol Razak, P. Metharom and M. Falasca, "Molecular and cellular mechanisms of chemoresistance in pancreatic cancer," Advances in Biological Regulation, vol. 68, pp. 77-87, 2018.
M. A. Tempero, M. M. P, A.-H. Mahmoud, A. Horacio, B. Andrew, B. S. W, B. I. A. B, B. Ellen, D. B. Cardin, C. Cha, E. G. Chiorean, C. Vincent and H. W. G, "Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology Version 2.2017," Journal of the National Comprehensive Cancer Network, vol. 15, no. 8, pp. 1028-1061, 2017.
D. B. Longley, D. P. Harkin and P. G. Johnston, "5-Fluorouracil: Mechanisms of action and clinical strategies," Nature Reviews Cancer, vol. 3, no. 5, pp. 330-338, 2003.
N. Bano, R. Najam, F. Qazi and A. Mateen, "Clinical features of oxaliplatin induced hypersensitivity reactions and therapeutic approaches," Asian Pacific Journal of Cancer Prevention, vol. 17, no. 4, pp. 1637-1641, 2016.
C. Bailly, "Irinotecan: 25 years of cancer treatment," Pharmacological Research, vol. 148, pp. 1-11, 2019.
G. Perri, L. Prakash, W. Qiao, G. Varadhachary, R. Wolff, D. Fogelman, M. Overman, S. Oant, M. Javle, E. Koay, J. Herman, M. Kim, N. Ikoma, C.-W. Tzeng, J. Lee and M. Katz, "Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma," Jama Surgery, vol. 155, no. 9, pp. 832-839, 2020.
A. Lambert, C. Gavoille and T. Conroy, "Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions," Therapeutic Advances in Gastroenterology, vol. 8, no. 631-645, p. 10, 2017.
Promega, "CellTiter-Glo Luminescent Cell Viability Assay," 2021. [Online]. Available: https://www.promega.com/products/cell-health-assays/cell-viability-and-cytotoxicity-assays/celltiter_glo-luminescent-cell-viability-assay/?catNum=G7570. [Accessed 23 4 2021].
J. Wang, D. C. Dead, F. J. Hornicek, H. Shi and Z. Duan, "RNA sequencing (RNA-Seq) and its application in ovarian cancer," Gynecologic Oncology, vol. 152, pp. 194-201, 2019.
American Type Culture Collection, "ATCC Credable leads to Incredible," ATCC, [Online]. Available: https://www.atcc.org. [Accessed 3 3 2021].
J. Lee, J.-c. Lee, M. A. Gromski, H. W. Kin, J. Kin, J. Kim and J.-H. Hwang, "Clinical outcomes of FOLFIRINOX in locally," Medicine, vol. 70, pp. 1-7, 2018.
D. D. Von Hoff, T. Ervin, F. P. C. G. E. Arena, I. Jeffrey, M. Moore, S. Thomas, S. A. Tjulandin, W. W. Ma, M. N. Saleh, M. Harris, M. Reni, S. Dowden, D. Laheru and M. F. Renschler, "Increased Survival in Pancreatic Cancer," The New England Journal of Medicine, vol. 369, no. 18, pp. 1691-1703, 2013.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Seth McKee; Victoria Del Gaizo Moore
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
